World's Best Scientists 2026 revealed!
Award Badge
Medicine
Spain
2023

D-Index & Metrics

Medicine

D-Index
118
Citations
68114
World Ranking
3990
National Ranking
2179

Manuel Hidalgo publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Manuel Hidalgo sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 773 publications — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Manuel Hidalgo D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Manuel Hidalgo sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 118 D-Index — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Medicine in Spain Leader Award

Overview

Manuel Hidalgo is affiliated with Cornell University in the United States and has a substantial research profile in medicine, with a focus on oncology and molecular biology. Their work primarily addresses pancreatic and hepatic oncology, cancer genomics and diagnostics, and cancer immunotherapy and biomarkers.

The scientist's main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these fields, Hidalgo has contributed significantly to subfields such as:

  • Oncology
  • Cancer Research
  • Molecular Biology
  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Their research topics often cover:

  • Pancreatic and Hepatic Oncology Research
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Cancer Research and Treatments
  • Cancer Cells and Metastasis
  • Advanced Breast Cancer Therapies
  • COVID-19 and healthcare impacts

Manuel Hidalgo has published in various notable journals, with frequent appearances in:

  • Journal of Clinical Oncology
  • Cancer Research
  • Clinical Cancer Research
  • Enfermedades Infecciosas y Microbiología Clínica
  • Cancer Cell

Some recent papers include:

  • "BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial" (2020) in Nature Medicine
  • "Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy" (2021) in Cell
  • "CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma" (2020) in Cancer Cell
  • "COVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort Study" (2020) in Journal of Clinical Oncology
  • "PDX-derived organoids model in vivo drug response and secrete biomarkers" (2020) in JCI Insight

Frequent co-authors collaborating with Hidalgo are:

  • Bruno Bockorny
  • Teresa Macarulla
  • Senthil K. Muthuswamy
  • Joseph E. Grossman
  • Jaime Feliú

Best Publications

  • Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

    Daniel D. Von Hoff;Thomas Ervin;Francis P. Arena;E. Gabriela Chiorean

  • Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

    Siân Jones;Xiaosong Zhang;D. Williams Parsons;D. Williams Parsons;Jimmy Cheng Ho Lin

  • Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

    David M. Hyman;Igor Puzanov;Vivek Subbiah;Jason E. Faris

  • Patient-derived xenograft models: an emerging platform for translational cancer research.

    Manuel Hidalgo;Frederic Amant;Andrew V. Biankin;Eva Budinská

  • Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

    Shirin Khambata-Ford;Christopher R. Garrett;Neal J. Meropol;Mark Basik

  • Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

    Manuel Hidalgo;Lillian L. Siu;John Nemunaitis;Jinee Rizzo

  • Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

    Daniel D. Von Hoff;Ramesh K. Ramanathan;Mitesh J. Borad;Daniel A. Laheru

  • Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

    Denis Soulieres;Neil N. Senzer;Everett E. Vokes;Manuel Hidalgo

  • Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

    Michael B. Atkins;Manuel Hidalgo;Walter M. Stadler;Theodore F. Logan

  • DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer

    Christine A. Iacobuzio-Donahue;Baojin Fu;Shinichi Yachida;Mingde Luo

  • Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy

    Manuel Hidalgo;S. Gail Eckhardt

  • Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

    Evanthia Galanis;Jan C. Buckner;Matthew J. Maurer;Jeffrey I. Kreisberg

  • The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

    Manuel Hidalgo;Eric K Rowinsky

  • Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment

    Viktor Grünwald;Manuel Hidalgo

  • Interrogating open issues in cancer precision medicine with patient-derived xenografts

    Annette T. Byrne;Denis G. Alférez;Frédéric Amant;Daniela Annibali

  • Pancreatic cancer: From state-of-the-art treatments to promising novel therapies

    Ignacio Garrido-Laguna;Manuel Hidalgo

  • Addressing the challenges of pancreatic cancer: future directions for improving outcomes

    Manuel Hidalgo;Stefano Cascinu;Jörg Kleeff;Roberto Labianca

  • Matrix metalloproteinase-2 contributes to cancer cell migration on collagen.

    Xiaoping Xu;Yao Wang;Zhihua Chen;Mark D. Sternlicht

  • Prognostic Significance of Tumorigenic Cells With Mesenchymal Features in Pancreatic Adenocarcinoma

    Zeshaan A. Rasheed;Jie Yang;Qiuju Wang;Jeanne Kowalski

  • Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity

    Linda A. deGraffenried;William E. Friedrichs;Douglas H. Russell;Elissa J. Donzis

Frequent Co-Authors

Antonio Jimeno
Antonio Jimeno University of Colorado Boulder
Anirban Maitra
Anirban Maitra The University of Texas MD Anderson Cancer Center
Wells A. Messersmith
Wells A. Messersmith University of Colorado Boulder
Daniel D. Von Hoff
Daniel D. Von Hoff Translational Genomics Research Institute
Ross C. Donehower
Ross C. Donehower Johns Hopkins University
Sharyn D. Baker
Sharyn D. Baker The Ohio State University
Alfredo Carrato
Alfredo Carrato University of Alcalá
Aik Choon Tan
Aik Choon Tan University of Utah
Francisco X. Real
Francisco X. Real Pompeu Fabra University
Aldo Scarpa
Aldo Scarpa University of Verona

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in Medicine but want more flexibility, there are several affordable online nursing degrees that may interest you. Online programs can help you balance your studies with work or personal responsibilities while preparing for a rewarding healthcare career.

For students seeking entry into nursing, some of the cheapest bsn programs online offer a cost-effective route toward becoming a registered nurse. Already an RN? The cheapest bsn programs allow current nurses to upgrade their credentials and boost their career opportunities.

Aspiring advanced practitioners can explore the cheapest online np programs, which train nurses to become nurse practitioners—a growing field with strong demand. For those interested in leadership, research, or academic roles, online nursing doctoral programs provide flexible doctoral options.

These online pathways can help launch or advance your healthcare career, often at a fraction of the cost and time of traditional programs.

Best Scientists Citing Manuel Hidalgo

Trending Scientists

Recently Published Articles